Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

J Clin Oncol. 2023 Jun 26:JCO2301239. doi: 10.1200/JCO.23.01239. Online ahead of print.NO ABSTRACTPMID:37364222 | DOI:10.1200/JCO.23.01239
Source: Clinical Breast Cancer - Category: Cancer & Oncology Source Type: research